
Bruno Bockorny MD FACP
@brunobockorny
Phase 1 Oncology | Drug Development | GI oncology @BIDMCHealth, Assistant Professor at Harvard @HarvardMed.
ID: 788922619005403137
https://www.dfhcc.harvard.edu/insider/member-detail/member/bruno-bockorny-md/ 20-10-2016 01:59:44
695 Tweet
1,1K Followers
1,1K Following





🔥Hot off the press📰Andrea Bullock, MD BIDMC Department of Medicine et al Nature Medicine: "Botensilimab Plus Balstilimab in R/R MSS mCRC: A Phase 1 Trial". ▶️BOT+BAL combo: manageable safety profile + encouraging clinical activity #ColorectalCancer #ClinicalTrial #CancerResearch #MedTwitter


nature.com/articles/s4159… fantastic innovation for refractory #colorectalcancer Dana-Farber Dana-Farber's Young-Onset Colorectal Cancer Center Dana-Farber News BIDMC Anthony El-Khoueiry Dr. Marwan G. Fakih Bruno Bockorny MD FACP Agenus


Botensilimab with expansion in MSS CRC; activity noted across multiple cold tumors - Anthony El-Khoueiry Steven O'Day, MD Joe Grossman Dr. Marwan G. Fakih Breelyn Wilky, MD 🎗 Rachel E. Sanborn, MD Ghassan Abou-Alfa Neil H. Segal MD PhD Bruno Bockorny MD FACP Agenus oncodaily.com/84424.html #Agenus #Cancer #OncoDaily #Oncology

This week, John Marshall highlighted research by Andrea J Bullock, Ben Schlechter, Dr. Marwan G. Fakih, Lia Tsimberidou, Breelyn Wilky, MD 🎗, Rachel E. Sanborn, MD, Ghassan Abou-Alfa, Neil H. Segal MD PhD, Bruno Bockorny MD FACP, Dhan Chand, Anthony El-Khoueiry and others in Nature Medicine. Learn more: bit.ly/3Vpa8nP.



CD40 agonist mitazalimab with mFOLFIRINOX in mPDAC #ESMOGI24 🔎OPTIMIZE-1 phase Ib/II study ✅study: ORR 42%, mDoR: 12.6 mo 👉mPFS: 7.7 mo, mOS: 14.9 mo 🧐promising data, phs-3 on the way.. #ESMOAmbassadors ESMO - Eur. Oncology


Liver transplantation + CTx vs CTx in unresectable CRC liver metastases 🔎TransMet randomised trial The Lancet doi.org/10.1016/S0140-… 👉5-yr OS: 56.6 vs 12.6% 👉Recurrence after LTx: 72% 🧐Impressive study, impressive results ❗️LTx valid option in highly selected pts ESMO - Eur. Oncology





New Clinical Cancer Research paper from Manuel Hidalgo 🇪🇸 🇺🇸 Bruno Bockorny MD FACP Senthil K Muthuswamy & colleagues: A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial aacrjournals.org/clincancerres/… Important trial that shows that technology

